The guidelines from the American Association for the Study of Liver Diseases (AASLD) define HBV reactivation as: 1) for HBsAg-positive, anti-HBc–positive patients: a 100-fold increase in HBV DNA levels compared to baseline, ≥1000 IU/mL in patients with previously undetectable levels, or ≥10,000 IU/mL if baseline levels are unavailable; 2) for HBsAg-negative, anti-HBc-positive patients: HBV DNA is detectable or reappearance of HBsAg (Terrault et al., 2018). Here, KRT88P is linked to liver disorder.